|
ISCO Has Developed Human Stem Cell Lines That Could Potentially Eliminate Problems of Immune Rejection International Stem Cell Corporation (OTCBB: ISCO) announced today that the Data Trends Equity Research Group, a unit of DataTrends Publications, Inc., publisher of Stem Cell Business News and the Guide to Stem Cell Research Companies, has released its Investor's Corporate Profile® of International Stem Cell Corporation. This timely, comprehensive report, published in PDF format, is available at http://www.stemcellresearchnews.com/DERG_Page.htm. International Stem Cell Corporation (ISCO.OB) has developed breakthrough human stem cell lines that they believe have the potential to eliminate the rejection of transplanted cells by the patient's immune system. ISCO's technology, parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs without the transfer of foreign DNA. This methodology offers the potential to create the first true "stem cell bank" and also addresses critical ethical issues by eliminating the need to use fertilized embryos. ISCO also produces and sells specialized cells and growth media worldwide for therapeutic research through its Maryland-based subsidiary, Lifeline Cell Technology. ISCO's goal is to be the world leader in providing human cells to study and cure disease. The Company plans to manufacture clinical and research products for the treatment of diabetes, liver disease, and retinal disease. In addition, ISCO is open to acquiring, partnering or forming joint ventures with companies that will be synergistic to its strategic endeavors. The Company is focused on human diseases that have already been shown in clinical tests to respond positively to cell transplantation (the use of functional human cells to replace cells that have been lost or damaged due to disease). ISCO has derived therapeutic cells from human parthenogenic stem cells (hpSCs) using technologies that promise to solve two critical problems with current cell transplantation methodologies: immune rejection, and a lack of sufficient cells to treat patients in need. The cells in development will not be derived from fertilized human embryos. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO's video, a fact sheet on the company, investor presentations, and more. About International Stem Cell Corporation (ISCO.OB): International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com. About DataTrends Publications, Inc., and DataTrends Equity Research Group DataTrends Publications, Inc., founded in 1987, is the publisher of Stem Cell Research News (founded 1999), Stem Cell Business News (2002), and Stem Cell Lab World (2007), as well as semi-annual Guide to Stem Cell Research Companies. DataTrends Equity Research Group, a unit of DataTrends Publications, provides independent research to small, growth-oriented public companies. DERG's Investor's Corporate Profile® is a comprehensive, detailed summary of a company's business and growth strategies, history, financial data, leadership, science & technology, commercial products and products in the pipeline, markets, competition, patent portfolio and other intellectual property, strategic alliances, and risk factors. The Profile does not forecast the market or provide target stock prices, and does not recommend buys, sells, or holds. DataTrends Publications, Inc., was not compensated by International Stem Cell Corporation, except for incidental printing, production, and other costs, if any, for the development of this Profile. Forward-Looking Safe Harbor Statement Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for International Stem Cell Corporation and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. These statements, and other forward-looking statements, are not guarantees of future performance. Both DataTrends Publications, Inc., and the Company disclaim any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman, CEO
kaldrich@intlstemcell.com
760-940-6383
or
Jeffrey Janus, President
jjanus@intlstemcell.com
760-940-6383
or
The Investor Relations Group
212-825-3210
Investor Relations:
Adam S. Holdsworth
aholdsworth@investorrelationsgroup.com
or
Media Relations:
Laura Colontrelle
lcolontrelle@investorrelationsgroup.com |
